Viking Global Investors LP Amylyx Pharmaceuticals, Inc. Transaction History

Viking Global Investors LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$27.71 - $40.93 $46.3 Million - $68.4 Million	-1,672,051 Reduced 36.08%	2,962,555 $86.9 Million
Q4 2022 Feb 14, 2023	SELL	$29.75 - $39.26 $33.8 Million - $44.6 Million	-1,135,930 Reduced 19.68%	4,634,606 $171 Million
Q3 2022 Nov 14, 2022	SELL	$17.15 - $30.92 $24 Million - $43.3 Million	-1,400,000 Reduced 19.52%	5,770,536 $162 Million
Q1 2022 May 16, 2022	BUY	$12.85 - $32.9 $92.1 Million - $236 Million	7,170,536 New	7,170,536 $92.1 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $308M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Viking Global Investors LP, based on Form 13F filings with the SEC.

Stay updated on Viking Global Investors LP with notifications on news.